ClinicalTrials.gg

Program

GZR33

A development code. Also written as “GZR33 Injection” and “GZR-33”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1, led by Gan & Lee Pharmaceuticals.

Furthest: phase 3, since Apr 8, 20265 company-led studies, 4 open or runningNext primary completion: Feb 2, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gan & Lee Pharmaceuticals54 open or runningphase 3since Apr 8, 2026Aug 8, 2024Feb 2, 2027phase 1 · NCT07918898

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 8, 2024First study: phase 1 study in Healthy SubjectsFirst studyNCT06548932 · 52 enrolled · China
  2. Aug 14, 2024Phase 2 study in Diabetes Mellitus, Type 2NCT06558708 · 60 planned · China
  3. Nov 17, 2025Phase 1 study in Type 1 Diabetes MellitisNCT07242664 · 12 planned · Germany
  4. Apr 8, 2026Phase 3 study in Diabetes Mellitus, Type 2Phase 3 reachedNCT07527078 · 350 planned · China
  5. Oct 27, 2026Phase 1 study in Healthy ParticipantsNCT07918898 · 26 planned

Ahead

  1. Feb 2, 2027Primary completion: phase 1 study in Healthy ParticipantsNCT07918898

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07918898Healthy Participants1Not yet recruitingFeb 2, 202726
NCT07527078Diabetes Mellitus, Type 2 · China3RecruitingApr 7, 2026350
NCT07242664Type 1 Diabetes Mellitis · Germany1RecruitingFeb 28, 202612
NCT06558708Diabetes Mellitus, Type 2 · China2RecruitingDec 202460
NCT06548932Healthy Subjects · China1CompletedFeb 24, 202352

How it is read

Names in the registry

  • “GZR33 Injection”, 4 entries
  • “GZR-33”, 1 entry

Codes read as this program: GZR33.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.